Stay updated on Pembrolizumab in Hypermutation Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:52:28.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a shift in the mutational load threshold for patients progressing under temozolomide to proceed to pembrolizumab treatment if the mutational load is now > 20 mutations/Mb. This change reflects an adjustment in the primary study hypothesis that tumors with acquired resistance to temozolomide become hypermutated and sensitive to pembrolizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:31.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for the study. Previously, this section had no information provided.
    Difference
    45%
    Check dated 2024-05-22T21:03:06.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:14:20.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.